668 related articles for article (PubMed ID: 18494826)
41. Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.
Gambichler T; Rotterdam S; Radkowski K; Altmeyer P; Kreuter A
Am J Clin Pathol; 2009 May; 131(5):710-4. PubMed ID: 19369632
[TBL] [Abstract][Full Text] [Related]
42. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings.
Tchernev G; Orfanos CE
J Cutan Pathol; 2007 Mar; 34(3):247-56. PubMed ID: 17302609
[TBL] [Abstract][Full Text] [Related]
43. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
44. Small and giant congenital melanocytic nevi as precursors to melanoma in children and adults.
Illig L
Pediatr Pol; 1986 Aug; 61(8):475-83. PubMed ID: 3574995
[No Abstract] [Full Text] [Related]
45. bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA; From L; Kahn HJ
Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
[TBL] [Abstract][Full Text] [Related]
46. Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas.
Bastian BC; Xiong J; Frieden IJ; Williams ML; Chou P; Busam K; Pinkel D; LeBoit PE
Am J Pathol; 2002 Oct; 161(4):1163-9. PubMed ID: 12368190
[TBL] [Abstract][Full Text] [Related]
47. p53 Protein expression in nevi and melanomas.
Cristofolini M; Boi S; Girlando S; Zumiani G; Cristofolini P; Dalla Palma P; Doglioni C; Barbareschi M
Arch Dermatol; 1993 Jun; 129(6):739-43. PubMed ID: 8507076
[TBL] [Abstract][Full Text] [Related]
48. Number of acquired melanocytic nevi in patients with melanoma and control subjects in Japan: Nevus count is a significant risk factor for nonacral melanoma but not for acral melanoma.
Rokuhara S; Saida T; Oguchi M; Matsumoto K; Murase S; Oguchi S
J Am Acad Dermatol; 2004 May; 50(5):695-700. PubMed ID: 15097952
[TBL] [Abstract][Full Text] [Related]
49. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
[TBL] [Abstract][Full Text] [Related]
50. [Congenital pseudomelanoma].
Kerl H; Smolle J; Hödl S; Soyer HP
Z Hautkr; 1989 Jul; 64(7):564, 567-8. PubMed ID: 2773538
[TBL] [Abstract][Full Text] [Related]
51. [Immunohistochemical analysis of ras gene expression in human melanomas and melanocytic nevi].
Yasuda H
Hokkaido Igaku Zasshi; 1989 May; 64(3):243-53. PubMed ID: 2670726
[TBL] [Abstract][Full Text] [Related]
52. Progressive derailment of cell cycle regulators in endometrial carcinogenesis.
Horrée N; van Diest PJ; van der Groep P; Sie-Go DM; Heintz AP
J Clin Pathol; 2008 Jan; 61(1):36-42. PubMed ID: 17483252
[TBL] [Abstract][Full Text] [Related]
53. [Immunohistochemical markers for cytoplasmic antigens in acquired melanosis, malignant melanomas, and nevi of the conjunctiva].
Hitzer S; Bialasiewicz AA; Richard G
Klin Monbl Augenheilkd; 1998 Oct; 213(4):230-7. PubMed ID: 9848068
[TBL] [Abstract][Full Text] [Related]
54. [Nevus cell nevi of the congenital type as possible forerunners of malignant melanomas].
Gartmann H
Z Hautkr; 1986 Jun; 61(11):763-5. PubMed ID: 3739394
[No Abstract] [Full Text] [Related]
55. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
[TBL] [Abstract][Full Text] [Related]
56. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions.
Lebe B; Pabuççuoğlu U; Ozer E
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):160-4. PubMed ID: 17525627
[TBL] [Abstract][Full Text] [Related]
57. Apolipoprotein D expression in cutaneous malignant melanoma.
Miranda E; Vizoso F; Martín A; Quintela I; Corte MD; Seguí ME; Ordiz I; Merino AM
J Surg Oncol; 2003 Jun; 83(2):99-105. PubMed ID: 12772203
[TBL] [Abstract][Full Text] [Related]
58. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma.
Banky JP; Kelly JW; English DR; Yeatman JM; Dowling JP
Arch Dermatol; 2005 Aug; 141(8):998-1006. PubMed ID: 16103329
[TBL] [Abstract][Full Text] [Related]
59. "Triggered trap": nevoid malignant melanoma.
McNutt NS
Semin Diagn Pathol; 1998 Aug; 15(3):203-9. PubMed ID: 9711670
[TBL] [Abstract][Full Text] [Related]
60. Cell adhesion and communication proteins are differentially expressed in melanoma progression model.
Rezze GG; Fregnani JH; Duprat J; Landman G
Hum Pathol; 2011 Mar; 42(3):409-18. PubMed ID: 21193224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
